首页AutophagyCannabinoid Receptor
Cannabinoid Receptor
T10510 CB1 antagonist 1 CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disord
T10694 CB1 inverse agonist 1 CB1 inverse agonist 1 is an orally active, and specific inverse agonist of the CB1 receptor (IC50s: 7.5 nM and 4100 nM for CB1 and CB2 receptors) with anorexigenic effects.
T13081 Taranabant racemate Taranabant racemate is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor.
T14204 6-Iodopravadoline 6-Iodopravadoline (AM630) is an antagonist of CB2 (Ki: 31.2 nM). And it shows 165-fold selectivity more than CB1 receptors.
T14302 Olorinab Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2.
T14504 BAY 38-7271 BAY 38-7271 has strong neuroprotective properties.[1] BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist. With Kis of 1.85 nM and 5.96 nM for recom
T1519 Rimonabant hydrochloride Rimonabant hydrochloride is a cannabinoid receptor antagonist, binding selectively to central cannabinoid receptors (CB1) with high affinity.
T1519L Rimonabant Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a redu
T16928 SR144528 SR144528 is an effective and selective antagonist of the CB2 receptor (Ki: 0.6 nM).
T17027 Tedalinab Tedalinab is an effective and selective cannabinoid receptor 2 agonist. Tedalinab has the potential for neuropathic pain and osteoarthritis treatment. Tedalinab has >4700-fold func
T1796 Otenabant hydrochloride Otenabant hydrochloride (CP-945598) is a competitive, high affinity, selective antagonist of the CB1 receptor (Ki: 0.7 nM).
T1915 AM251 AM251 is a effective CB1 receptor antagonist (IC50/Ki: 8 /7.49 nM) that displays 306-fold selectivity over CB2 receptors; also effective GPR55 agonist (EC50: 39 nM).
T2264 AM281 AM 281, a cannabinoid antagonist, reduces neurologic dysfunction and mortality rate after cecal ligation and puncture in rats.
T2635 Org 27569 Org 27569, an allosteric modulator of cannabinoid CB1 receptor, can induce a CB1 receptor state that is characterized by decreased inverse agonist affinity and enhanced agonist aff
T3530 Otenabant Otenabant has been investigated for the treatment of Obesity.
T3699 Bay 59-3074 Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic p
T3S0738 yangonin 1. Yangonin is a novel CB₁ receptor ligand, it exhibits affinity for the human recombinant CB₁ receptor. 2. Yangonin could be a valuable candidate for the intervention of NF-κ
T4453 JD5037 JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
T4458 WIN 55,212-2 Mesylate WIN 55, 212-2 (Mesylate) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Kis of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.
T4654 SLV319 SLV319 has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.
T5996 CB1-IN-1 CB1-IN-1 is a peripherally restricted CB1R antagonist, for CB1R and CB2R with Ki of 0.3 nM and 21 nM,respectively.
T6417 BML190 BML-190 is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.
T6527 GW842166X GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.
T6755 AM1241 AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor.
T7316 LY2828360 LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM). It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively).
T7375 A-836339 A-836339 acts as a potent cannabinoid receptor full agonist which has a higher affinity for the peripheral CB2 receptor (Ki = 0.64 nM) over the central CB1 receptor (Ki = 270 nM).
T7705 GW 405833 GW 405833 is an agonist of cannabinoid-2 (CB(2)) receptor-selective
T8511 TM38837 TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.
T9114 β-Caryophyllene β-Caryophyllene is a CB2 receptor agonist.
TN2268 Tetrahydromagnolol Tetrahydromagnolol can activate cannabinoid (CB) receptors.
TN5131 Tetrahydrocannabivarin Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile s
TQ0173 MDA 19 MDA 19 is a specific human CB2 receptor agonist (Ki: 43.3 nM).
TWS0414 Cannabidiol Cannabidiol is GPR55 and weak CB1 antagonist (IC50s: 0.445 and 3.35 μM), CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50: 27.5 μM). It also a weak agonist a
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。